Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database
Nephrology Dialysis Transplantation · 22.06.2026
DOI: 10.1093/ndt/gfag144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.06.2026. Verfasst von Jinshan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Institute, Zunyi Medical University, Zunyi, China. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Science and Technology Support Program of Guizhou Province.
Abstract (Originalsprache)
Background and objective Difelikefalin, a peripherally acting selective κ-opioid receptor agonist, is approved for treating chronic kidney disease-associated pruritus in adults on hemodialysis. However, real-world data on its adverse drug events (ADEs) remain limited. This study aimed to systematically identify ADE signals associated with difelikefalin in hemodialysis patients using the FDA Adverse Event Reporting System (FAERS) database, to generate hypotheses for subsequent clinical validation and provide targeted evidence for safe clinical application of difelikefalin in this vulnerable population.
Methods
ADE reports related to difelikefalin were extracted from the FAERS database (2022–2025). Drug names were standardized using Medex UIMA software, and ADEs were coded according to the Medical Dictionary for Regulatory Activities. Disproportionality analyses, including the reporting odds ratio (ROR) and proportional reporting ratio, were employed to detect ADE signals.
Results
A total of 328 difelikefalin-related ADE reports were included, which is limited by the relatively recent approval and limited real-world use of this agent. Demographically, male patients (49.09%) outnumbered females (24.09%), and the vast majority of patients with clear age data were aged 65 years or older. Clinically, the most frequent outcomes were “other serious” events (46.01%), hospitalization (33.46%), and death (15.59%). At the System Organ Class level, “Nervous system disorders” (ROR = 3.4) and “Psychiatric disorders” (ROR = 2.99) showed the strongest ADE signals. At the Preferred Term level, high-risk signals included mental status changes (ROR = 85.65), disorientation (ROR = 33.62), electric shock sensation (ROR = 32.09), somnolence (ROR = 16.25), fall (ROR = 8.46), and fracture (ROR = 21.06). We also identified several rare ADE signals unreported in Phase III clinical trials (e.g. electric shock sensation and disorientation) with significant disproportional reporting.
Conclusion
This pharmacovigilance study identifies potential neuropsychiatric safety signals associated with difelikefalin, with a particularly elevated risk in elderly patients. These findings identify elderly hemodialysis patients as the high-risk group for difelikefalin-related ADEs, and suggest the need for targeted clinical monitoring strategies for this population; all signals require prospective cohort studies to validate potential causal relationships.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Institute, Zunyi Medical University, Zunyi, China.
- Department of Immunology, Zunyi Medical University, Zunyi, China.
- Department of Histology and Embryology, Zunyi Medical University, Zunyi, China.
ORCID-Profile: Jun Tan
Förderung
- Science and Technology Support Program of Guizhou Province
Zitieren
APA
Zhao, J., Qiu, Q., Zhang, J., & Tan, J. (2026). Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag144
Vancouver
Zhao J, Qiu Q, Zhang J, Tan J. Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag144
BibTeX
@article{Zhao2026,
author = {Zhao, Jinshan and Qiu, Quanyu and Zhang, Jidong and Tan, Jun},
title = {Difelikefalin-associated adverse drug event signals: a real-world pharmacovigilance study from the FAERS database},
journal = {Nephrology Dialysis Transplantation},
year = {2026},
doi = {10.1093/ndt/gfag144}
}
EUVIMED